Daunorubicin

Kura Oncology Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 10, 2023
KRAS, AACR, Postcholecystectomy syndrome, European Hematology Association, CRH, Cancer, Lung cancer, Kura, ID, FTI, PI3, Daunorubicin, Acute myeloid leukemia, Renal cell carcinoma, Congress, AML, Azacitidine, Dor, Investment, Patient, EGFR, KURA, EHA, CR, FLT3, Webcast, Research, Axitinib, FDA, Safety, IND, Disease, Video game, Pharmaceutical industry, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the first quarter of 2023 were $25.2 million, compared to $20.9 million for the first quarter of 2022.
  • General and administrative expenses for the first quarter of 2023 were $11.4 million, compared to $11.9 million for the first quarter of 2022.
  • ET / 1:30 p.m. PT today, May 10, 2023, to discuss the financial results for the first quarter 2023 and to provide a corporate update.

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023

Retrieved on: 
Thursday, April 27, 2023
Docetaxel, Abstract, BeiGene, American Society of Clinical Oncology, Research, Lurbinectedin, Daunorubicin, ASCO, Patient, Cytarabine, Cancer, Annual general meeting, Pivotal, Jazz Pharmaceuticals, BTC, FDA, Society, Bone marrow, Medical imaging, Nightclub, Pharmaceutical industry, Jazz

DUBLIN, April 27, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present nine abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Presentations include clinical data from trials of zanidatamab, Zepzelca® (lurbinectedin) and Vyxeos® (daunorubicin and cytarabine).

Key Points: 
  • Presentations include clinical data from trials of zanidatamab, Zepzelca® (lurbinectedin) and Vyxeos® (daunorubicin and cytarabine).
  • "The breadth of oncology data being presented by Jazz and our partners reflects our relentless focus on raising the standard of care for some of the most difficult-to-treat cancers."
  • Pivotal data from the Phase 2b study of the bispecific antibody zanidatamab in previously treated HER2-amplified BTC was selected by ASCO as an oral presentation.
  • Other presentations at the annual meeting feature data from our oncology pipeline and current product portfolio, across a range of solid tumors and hematological malignancies, include:
    The full ASCO abstracts will be available on May 25, 2023, after 5 p.m.

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023

Retrieved on: 
Thursday, April 27, 2023
Docetaxel, Abstract, BeiGene, American Society of Clinical Oncology, Research, Lurbinectedin, Daunorubicin, ASCO, Patient, Cytarabine, Cancer, Annual general meeting, Pivotal, Jazz Pharmaceuticals, BTC, FDA, Society, Bone marrow, Medical imaging, Nightclub, Pharmaceutical industry, Jazz

DUBLIN, April 27, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present nine abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Presentations include clinical data from trials of zanidatamab, Zepzelca® (lurbinectedin) and Vyxeos® (daunorubicin and cytarabine).

Key Points: 
  • Presentations include clinical data from trials of zanidatamab, Zepzelca® (lurbinectedin) and Vyxeos® (daunorubicin and cytarabine).
  • "The breadth of oncology data being presented by Jazz and our partners reflects our relentless focus on raising the standard of care for some of the most difficult-to-treat cancers."
  • Pivotal data from the Phase 2b study of the bispecific antibody zanidatamab in previously treated HER2-amplified BTC was selected by ASCO as an oral presentation.
  • Other presentations at the annual meeting feature data from our oncology pipeline and current product portfolio, across a range of solid tumors and hematological malignancies, include:
    The full ASCO abstracts will be available on May 25, 2023, after 5 p.m.

Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
Safety, Bristol Myers Squibb, ID, FTI, FLT3, Cancer, QT interval, III, Farnesol, EGFR, IDH, Disease, EORTC, Organization, Research, IND, Webcast, FDA, Investment, Patient, Element, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ASH, KRAS, PI3, CRH, Azacitidine, Renal cell carcinoma, Kura, KURA, Society, AML, HNSCC, Head, CR, PIK3CA, Daunorubicin, Data, Food, G&A, Lung cancer, Acute myeloid leukemia, Pharmaceutical industry, Video game

ET –

Key Points: 
  • ET –
    SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2022 financial results and provided a corporate update.
  • Research and development expenses for the fourth quarter of 2022 were $22.7 million, compared to $21.0 million for the fourth quarter of 2021.
  • General and administrative expenses for the fourth quarter of 2022 were $12.5 million, compared to $12.1 million for the fourth quarter of 2021.
  • ET / 1:30 p.m. PT today, February 23, 2023, to discuss the financial results for the fourth quarter and full year 2022 and to provide a corporate update.

CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

Retrieved on: 
Thursday, December 8, 2022
Society, Security (finance), Randomness, Lymphoma, Form 10-K, Physician, Brain, Reata Pharmaceuticals, KPS, Glioblastoma, II, Cell proliferation, MD, MD Anderson Cancer Center, Central nervous system, Blood–brain barrier, University, Daunorubicin, Doctor of Philosophy, CNS, Fiat 500X, MGMT, Patient, BSA, DNA, Cancer, BBB, OS, Pakistan Society of Neuro-Oncology, Traffic barrier, Drug Quality and Security Act, Disease, FDA, Anthracycline, Multimedia, Clinical trial, Clinical study design, Safety, Risk, GBM, Doxorubicin, Medicinal chemistry, Pharmaceutical industry, Medical imaging, Lomustine

HOUSTON, Dec. 8, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced preliminary results from its ongoing potentially pivotal trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM).

Key Points: 
  • "Berubicin continues to demonstrate its ability to be an innovative treatment in GBM as a safe and potentially effective therapy.
  • These preliminary findings bolster our conviction in Berubicin as we continue to advance this study forward.
  • Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
  • CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM

Retrieved on: 
Friday, October 7, 2022
News, U.S. Securities and Exchange Commission, Fiat 500X, GBM, Drug Quality and Security Act, Orphan, Daunorubicin, SEC, Hope, Traffic barrier, Glioblastoma, Lomustine, NDA, NASDAQ, Patient, Brain, Standard of care, Security (finance), Central nervous system, Securities Act of 1933, Private Securities Litigation Reform Act, Solution, Form 10-K, IBN, Company, Marketing, Overload, CEO, Awareness, Adult, Securities Exchange Act of 1934, Safety, CNS, Lymphoma, GLOBE, Clinical trial, Forward-looking statement, Terminology, FDA, Risk, Pharmaceutical industry

The audio news release covers CNS Pharmaceuticals recent announcement highlighting the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.

Key Points: 
  • The audio news release covers CNS Pharmaceuticals recent announcement highlighting the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
  • This is a true testament to our team's commitment to and the execution of this important clinical program.
  • Berubicin is currently being evaluated in a potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM.
  • CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.

CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 7, 2022
Brain, Daunorubicin, Fiat 500X, GBM, Central nervous system, View, NASDAQ, Traffic barrier, Multimedia, Conference, Glioblastoma, Company, Investor, Event, CNS, Lymphoma, Pharmaceutical industry

HOUSTON, Sept. 7, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Key Points: 
  • HOUSTON, Sept. 7, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.
  • In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
  • CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.

Outlook on the Pharmaceutical Processing Seals Global Market to 2030 - Featuring Trelleborg, Freudenberg and IDEX Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 14, 2022
Packaging, Pharmaceutical, Health, Manufacturing, Woman, Adult, Silicone, Mark (given name), Temperature, FLT3, AML, Growth, BDR, Daunorubicin, Silicon, Neoplasm, USD, Renewable energy, Pharmaceutical industry, Application

The global pharmaceutical processing seals market size is expected to reach USD 4.92 billion by 2030, according to a new study.

Key Points: 
  • The global pharmaceutical processing seals market size is expected to reach USD 4.92 billion by 2030, according to a new study.
  • The requirement for pharmaceutical processing seals is quite high due to the increased demand for cleanliness and sanitation.
  • Pharmaceutical processing covers are predicted to be in high demand due to capacity growth and ongoing innovation in the pharmaceutical sector.
  • The publisher has segmented the pharmaceutical processing seals market report based on type, material, application, and region:

Roswell Park Expert to Present on Effectiveness of New Combination for Acute Myeloid Leukemia

Retrieved on: 
Monday, June 6, 2022
National Cancer Institute, Society, Upstate New York, Nausea, American Society of Clinical Oncology, FLT3, ASCO, AML, Hope, Annual general meeting, Daunorubicin, Patient, Acute myeloid leukemia, Roswell Park Comprehensive Cancer Center, ITD, CDT, Idarubicin, Cytarabine, MD, Clinical trial, Diarrhea, Hematology, TKD, Febrile neutropenia, Crenolanib, Pharmaceutical industry, Leukemia, Allotransplantation, Myelodysplastic syndrome

CHICAGO, June 6, 2022 /PRNewswire-PRWeb/ -- On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML). Dr. Wang will discuss the findings at the American Society of Clinical Oncology (ASCO) annual meeting 2022, at 11:57 a.m. CDT, in Hall S, room 100a, during the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant oral abstract session (abstract 7007).

Key Points: 
  • CHICAGO, June 6, 2022 /PRNewswire-PRWeb/ -- On Tuesday, June 7, Eunice Wang, MD , Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).
  • After one treatment cycle, 73% of patients experienced clinical responses, and 86% of patients responded to treatment after two cycles.
  • Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York.
  • Rebecca Vogt, Roswell Park Comprehensive Cancer Center, 716-548-0482, [email protected]
    Annie Deck-Miller, Roswell Park Comprehensive Cancer Center, 716-845-8593, [email protected]

CNS Pharmaceuticals Announces Presentation at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Tuesday, May 24, 2022
GBM, Traffic barrier, Company, Multimedia, Brain, NASDAQ, Daunorubicin, Investor, Lymphoma, CNS, Conference, Glioblastoma, Central nervous system, Fiat 500X, Pharmaceutical industry

HOUSTON, May 24, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals, will be participating at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

Key Points: 
  • HOUSTON, May 24, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco , Chief Executive Officer of CNS Pharmaceuticals, will be participating at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.
  • In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
  • CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.